Sandoz launches new global health inequalities initiative
‘Act4Biosimilars’ will improve patient access and increase adoption in over 30 countries by 2030
Read More
Tag: biosimilars
Record number of cancer drugs launched in 2018, says report
The IQVIA report also explores health system barriers hindering the realisation of the benefits of those therapies and drug candidates.
Read More
Global medicine spend forecast to exceed $1.5 trillion by 2023
A new report containing the latest predictions for the global pharmaceutical market has found that global spending on medicines is set to exceed $1.5 trillion by 2023 – marking a 50% increase within seven years.
Read More
Sandoz launches MabThera, Enbrel biosimilars in the UK
Novartis group Sandoz has launched two new biosimilars across the UK potentially expanding access to biologic treatments for a range of inflammatory conditions and blood cancers.
Read More
MSD accused of breaching UK competition law
The UK’s Competition and Markets Authority (CMA) has provisionally found that a discount scheme operated by MSD for its biologic Remicade may have restricted competition from cheaper biosimilar versions of the drug entering the market.
Read More
Merck sells biosimilars business to Fresenius
Merck has divested its biosimilars business to fellow German drugmaker Fresenius in a deal potentially worth 670 million euros.
Read More
First Humira biosimilar approved in Europe
Amgen has won European approval for its first biosimilar, a version of AbbVie’s blockbuster Humira (adalimumab).
Read More
Shire steps away from biosimilars
Shire has handed back rights to the two biosimilars it acquired through its recent purchase of Baxalta, retaining its focus on the development of drugs for rare diseases.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
